AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD 0.0030
-0.0010 (-25.00%)
Aug 26, 2026, 9:59 AM AEST
AdAlta Revenue
In the fiscal year ending June 30, 2026, AdAlta had annual revenue of 478.23K AUD, down -29.36%. AdAlta had revenue of 306.15K in the half year ending December 31, 2025, a decrease of -73.14%.
Revenue
478.23K
Revenue Growth
-31.25%
P/S Ratio
20.15
Revenue / Employee
n/a
Employees
1
Market Cap
9.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 478.23K | -198.78K | -29.36% |
| Jun 30, 2025 | 677.01K | -1.06M | -61.04% |
| Jun 30, 2024 | 1.74M | -1.73M | -49.91% |
| Jun 30, 2023 | 3.47M | 715.56K | 25.99% |
| Jun 30, 2022 | 2.75M | -1.23M | -30.89% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| Neurotech International | 7.07M |
| Cambium Bio | 668.79K |
| Bio-Gene Technology | 390.63K |
| ReNerve | 333.21K |
| Invex Therapeutics | 229.08K |
| Patrys | 100.38K |
| Vectus Biosystems | 89.96K |
AdAlta News
- 5 days ago - AdAlta Annual report: H2 2026 - Filings
- 13 days ago - AdAlta Slides: Investor presentation - Filings
- 5 weeks ago - AdAlta Slides: Investor presentation - Filings
- 3 months ago - AdAlta Transcript: Investor update - Transcripts
- 3 months ago - AdAlta Slides: Investor update - Filings
- 4 months ago - AdAlta Earnings release: Q3 2026 - Filings
- 6 months ago - AdAlta Quarterly report: H1 2026 - Filings
- 7 months ago - AdAlta Slides: Investor presentation - Filings